Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 7/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 6/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689128 | 0.98 | MMP1 (0.65) | MMP1SMN1; SMN2FFAR1CETPMMP13 | |
| SCHEMBL6866226 | 0.92 | MMP1 (0.55) | MMP1SMN1; SMN2FFAR1CETPMMP13 | |
| SCHEMBL27561065 | 0.91 | MMP1 (0.56) | MMP1SMN1; SMN2FFAR1CETPMMP13 | |
| SCHEMBL6862342 | 0.91 | MMP1 (0.59) | MMP1SMN1; SMN2FFAR1CETPMMP13 | |
| SCHEMBL27500507 | 0.90 | MMP1 (0.54) | MMP1SMN1; SMN2FFAR1CETPMMP13 | |
| SCHEMBL6813091 | 0.90 | MMP1 (0.76) | MMP1SMN1; SMN2FFAR1CETPMMP13 | |
| SCHEMBL6870847 | 0.88 | MMP1 (0.55) | MMP1SMN1; SMN2FFAR1CETPMMP13 | |
| SCHEMBL6691684 | 0.88 | MMP1 (0.79) | MMP1SMN1; SMN2FFAR1CETPMMP13 | |
| SCHEMBL6813465 | 0.88 | MMP1 (0.55) | MMP1SMN1; SMN2FFAR1CETPMMP13 | |
| SCHEMBL6862333 | 0.85 | MMP1 (0.50) | MMP1SMN1; SMN2FFAR1CETPMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1068180-B1 | PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTENASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-15 | — | — | EP | disclosed |
| CN-1171866-C | Aryloxyarylsulfonylamino hydroxamic acid derivatives | �Ʒ� | 2004-10-20 | — | — | CN | disclosed |
| EP-1415984-A1 | Aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1003720-B1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-0949246-B1 | Process for preparing phenoxyphenylsulfonyl halides | PFIZER PROD INC (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-0949245-B1 | Process for alkylating hindered sulfonamides | PFIZER PROD INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6288246-B1 | REACTION OF HYDROXYLAMINE WITH ALKYLSILYL HALIDE, HYDROLYSIS WITH ACID | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| US-20010011143-A1 | Process for preparing phenoxyphenylsulfonyl halides | HAWKINS JOEL M (US) | 2001-08-02 | — | — | US | disclosed |
| CN-1296474-A | Alkylation of hindered sulfonamides for the preparation of matrix metalloproteinase inhibitors | PFIZER PROD INC (US) | 2001-05-23 | — | — | CN | disclosed |
| US-6229025-B1 | MICHAEL ADDITION TO PROPIOLATES | PFIZER INC | 2001-05-08 | — | — | US | disclosed |
| US-6118016-A | Process for preparing phenoxyphenylsulfonyl halides | PFIZER INC. (US) | 2000-09-12 | — | — | US | disclosed |
| CN-1265646-A | Aryloxyarylsulfonylamino hydroxamic acid derivatives | PFIZER PROD INC (US) | 2000-09-06 | — | — | CN | disclosed |
| US-6114568-A | Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors | PFIZER INC. (US) | 2000-09-05 | — | — | US | disclosed |
| CN-1238329-A | Process for preparing phenoxyphenylsulfonyl halides | PFIZER PROD INC (US) | 1999-12-15 | — | — | CN | disclosed |
| CN-1234396-A | Process for alkylating hindered sulfonamides | PFIZER PRODUCTS CO (US) | 1999-11-10 | — | — | CN | disclosed |
| WO-1999052862-A1 | PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| CN-1232023-A | Process for preparing hydroxamic acids | PFIZER PROD INC (US) | 1999-10-20 | — | — | CN | disclosed |
| EP-0949244-A2 | Process for preparing hydroxamic acids | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0949245-A1 | Process for alkylating hindered sulfonamides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0949246-A1 | Process for preparing phenoxyphenylsulfonyl halides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011143-A1 | Process for preparing phenoxyphenylsulfonyl halides | MMP2, MMP3, MMP14 | MMP1 10/4885SMN1; SMN2 2818/4885FFAR1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.